This webinar discusses the use of antibody-drug conjugates (ADCs) and associated proactive toxicity management to assist patients to adhere to their treatment protocols therefore improving patient outcomes.
Belantamab mafodotin is now TGA-registered for people with multiple myeloma who have had at least one prior line of therapy. Available exclusively to CNSA members, we encourage you to login and listen today!
